CytoDyn (OTC: CYDY) Monoclonal antibody HIV treatment w potential FDA approval in 2019

CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer.

The company is at a key inflection point, with potential FDA approval for PRO140 for treating HIV expected in 2019. Dr. Pourhassan explains the PRO140 technology, its numerous advantages over current HIV therapies on the market, market potential, as well as expanding PRO140’s indications for treating cancer.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.